Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer
Top Cited Papers
- 15 January 2001
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (2) , 289-298
- https://doi.org/10.1200/jco.2001.19.2.289
Abstract
PURPOSE: To determine the safety, humoral immune response replication, and activity of multiple intratumoral injections of ONYX-015 (replication selective adenovirus) in patients with recurrent squ...Keywords
This publication has 64 references indexed in Scilit:
- Synergistic effect of ONYX-015 and chemotherapy on lung cancer cell lines and primary culturesLung Cancer, 2000
- 843: Phase II study of vinorelbine (NVB) in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)European Journal Of Cancer, 1997
- Further abstracts2. BiologyAnnals of Oncology, 1996
- Safety Evaluation of Ad5CMY-p53 In VitroandIn VivoHuman Gene Therapy, 1995
- Head and Neck CancerNew England Journal of Medicine, 1993
- Active specific immunotherapy with Newcastle-diseasevirus-modified autologous tumor cells following resection of liver metastases in colorectal cancerCancer Immunology, Immunotherapy, 1992
- p53 and DNA polymerase α compete for binding to SV40 T antigenNature, 1987
- ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMAThe Lancet, 1973
- Superinfection of tumors with virusesCellular and Molecular Life Sciences, 1969
- Studies on the biological characteristics of the newcastle disease virus (NDV) adapted to the brain of newborne miceArchiv für die gesamte Virusforschung, 1957